IN BRIEF: Syncona s Gyroscope Reports Positive Results From GT005 Test
Fri, 12th Feb 2021 16:24
Syncona Ltd - London-based life sciences investor - Portfolio firm Gyroscope Therapeutics Ltd announces positive interim safety, protein expression and biomarker data from the open-label Phase I/II Focus clinical trial of its gene therapy GT005, for patients with geographic atrophy secondary to age-related macular degeneration.
Data showed that GT005 was well tolerated in patients. We are highly encouraged by the early data from Gyroscope s Phase I/II Focus trial, which suggests that the administration of GT005 leads to sustained expression of CFI and down-regulation of the complement system - a part of the inflammatory system which has been strongly linked as a cause of dry AMD, said Chris Hollowood, chief investment officer of Syncona Investment Management Ltd.
11 February 2021 · Further commitment of £25.3 million in a £61.0 million expanded Series A; taking Syncona s total commitment to Quell to £59.3 million · First company globally targeting liver transplantation with engineered T regulatory cell therapy; set for clinical entry in the first half of 2022 · Research programmes initiated in Type 1 Diabetes ( T1D ) and Amyotrophic Lateral Sclerosis ( ALS ) Syncona Ltd ( Syncona ) announces a £25.3 million new commitment in a £61.0 million expanded Series A financing for Quell Therapeutics ( Quell ). This is the largest amount of funding to date for any stand-alone engineered T regulatory cell (Treg) company and this new commitment takes Syncona s total commitment to this business to £59.3 million. Syncona has invested £35.1 million of its total commitment and values its investment at that amount (equivalent to cost). Syncona will have a 74 per cent fully diluted o
Quell Therapeutics Expands Series A Financing to $84 Million
Search jobs
Quell Therapeutics Expands Series A Financing to $84 Million
– Largest Series A in the Treg field –
London, UK – February 11 2021 – Quell Therapeutics Ltd (“Quell”), a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the closing of an extended Series A financing led by their existing investors Syncona Ltd (“Syncona”), who have committed an additional $34.7 million and UCL Technology Fund (“UCLTF”) who have committed an additional $1 million; bringing the total Series A financing to circa $84 million.
Quell is funded to progress its program in liver transplantation to clinical proof of concept, whilst expanding its portfolio into autoimmune and neuroinflammatory diseases. Additionally, the funding will allow the Company to further develop scalable manufacturing processes and expand its senior leadership team.
By BFN News | 07:32 AM | Wednesday 06 January, 2021 Autolus Therapeutics, a portfolio company of healthcare company Syncona, will reduce its headcount by 20% in Q1, which will deliver cost savings of around $15 million, as part of its decision to focus and prioritise the development of the AUTO1 programme.
Autolus will seek partnership opportunities to fund additional clinical development plans for AUTO3, in relapsed/refractory diffuse large B cell lymphoma (DLBCL), currently in a Phase 1/2 trial, before progressing the programme into the next phase of development.
The company will continue to build and leverage its platform and capability to progress its pipeline of next generation programmes in paediatric ALL (AUTO1/22) and peripheral T Cell Lymphoma (AUTO4) (which are currently in clinical trials), and multiple myeloma (AUTO8), neuroblastoma (AUTO6NG), peripheral T Cell Lymphoma (AUTO5) and prostate cancer (AUTO7) (which are currently in pre-clinical development).